Literature DB >> 15652648

Importance of the central region of lamprey gonadotropin-releasing hormone III in the inhibition of breast cancer cell growth.

Krisztina Herédi-Szabó1, Jeremiah Lubke, Geza Toth, Richard F Murphy, Sándor Lovas.   

Abstract

Naturally occurring isoforms of the decapeptide gonadotropin-releasing hormone (GnRH) share residues 1-4 and 9-10. lGnRH-III, the third isoform isolated in the sea lamprey has no endocrine effect in mammals but shows a direct antiproliferative effect on human breast, prostate and endometrial cancer cell lines. To investigate these features, residues 5-8 of lGnRH-III were systematically replaced with Ala. The ability of the synthetic analogs to interact with receptors on MDA-MB 231 human breast cancer cells and their effect on the growth of the same cell line were investigated. [Ala6]lGnRH-III and [Ala7]lGnRH-III have neither receptor binding nor antiproliferative activity. Replacement of His5 with Ala resulted in an analog that binds to the receptor but does not have antiproliferative activity. The results are in agreement with previous reports that modifications of Lys at position 8 are well tolerated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15652648     DOI: 10.1016/j.peptides.2004.10.007

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.

Authors:  Gábor Mező; László Kőhidai; Livia Polgár; Eszter Lajkó; Pál Soós; Orsolya Láng; Marilena Manea; Béla Merkely
Journal:  Beilstein J Org Chem       Date:  2018-06-28       Impact factor: 2.883

2.  Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.

Authors:  Eszter Lajkó; Rózsa Hegedüs; Gábor Mező; László Kőhidai
Journal:  Int J Mol Sci       Date:  2019-09-08       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.